Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Intravenous Propofol Versus Volatile Anesthetics For Stroke Endovascular Thrombectomy.

Diprose WK, Wang MTM, Campbell D, Sutcliffe JA, McFetridge A, Chiou D, Lai J, Barber PA.

J Neurosurg Anesthesiol. 2019 Aug 23. doi: 10.1097/ANA.0000000000000639. [Epub ahead of print]

PMID:
31453877
2.

Evaluation of the In Vitro Activity of Eravacycline against a Broad Spectrum of Recent Clinical Anaerobic Isolates.

Snydman DR, McDermott LA, Jacobus NV, Kerstein K, Grossman TH, Sutcliffe JA.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02206-17. doi: 10.1128/AAC.02206-17. Print 2018 May.

3.

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Bacillus anthracis Infection in BALB/c Mice and Cynomolgus Macaques.

Grossman TH, Anderson MS, Drabek L, Gooldy M, Heine HS, Henning LN, Lin W, Newman JV, Nevarez R, Siefkas-Patterson K, Radcliff AK, Sutcliffe JA.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01103-17. doi: 10.1128/AAC.01103-17. Print 2017 Oct.

4.

Heterocyclyl tetracyclines. 2. 7-Methoxy-8-pyrrolidinyltetracyclines: discovery of TP-2758, a potent, orally efficacious antimicrobial against Gram-negative pathogens.

Sun C, Deng Y, Hunt DK, Fyfe C, Chen CL, Clark RB, Grossman TH, Sutcliffe JA, Xiao XY.

J Antibiot (Tokyo). 2018 Feb;71(2):287-297. doi: 10.1038/ja.2017.86. Epub 2017 Jul 26.

PMID:
28743974
5.

In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.

Seifert H, Stefanik D, Sutcliffe JA, Higgins PG.

Int J Antimicrob Agents. 2018 Jan;51(1):62-64. doi: 10.1016/j.ijantimicag.2017.06.022. Epub 2017 Jul 11.

PMID:
28705668
6.

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques.

Grossman TH, Anderson MS, Christ D, Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JA.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00448-17. doi: 10.1128/AAC.00448-17. Print 2017 Aug.

7.

Fluorocycline TP-271 Is Potent against Complicated Community-Acquired Bacterial Pneumonia Pathogens.

Grossman TH, Fyfe C, O'Brien W, Hackel M, Minyard MB, Waites KB, Dubois J, Murphy TM, Slee AM, Weiss WJ, Sutcliffe JA.

mSphere. 2017 Feb 22;2(1). pii: e00004-17. doi: 10.1128/mSphere.00004-17. eCollection 2017 Jan-Feb.

8.

Heterocyclyl Tetracyclines. 1. 7-Trifluoromethyl-8-Pyrrolidinyltetracyclines: Potent, Broad Spectrum Antibacterial Agents with Enhanced Activity against Pseudomonas aeruginosa.

Deng Y, Sun C, Hunt DK, Fyfe C, Chen CL, Grossman TH, Sutcliffe JA, Xiao XY.

J Med Chem. 2017 Mar 23;60(6):2498-2512. doi: 10.1021/acs.jmedchem.6b01903. Epub 2017 Mar 15.

PMID:
28248499
9.

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.

Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, Sutcliffe JA, Horn P.

JAMA Surg. 2017 Mar 1;152(3):224-232. doi: 10.1001/jamasurg.2016.4237.

PMID:
27851857
10.

Technical and Clinical Outcomes Following Colonic Stenting: A Seven-Year Analysis of 268 Procedures.

Little MW, Oakley T, Briggs JH, Sutcliffe JA, Allouni AK, Makris G, Bratby MJ, Tapping CR, Patel R, Wigham A, Anthony S, Phillips-Hughes J, Uberoi R.

Cardiovasc Intervent Radiol. 2016 Oct;39(10):1471-8. doi: 10.1007/s00270-016-1391-5. Epub 2016 Jun 3.

PMID:
27259863
11.

Erratum for Grossman et al., target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA.

Antimicrob Agents Chemother. 2015 Sep;59(9):5870. doi: 10.1128/AAC.01551-15. No abstract available.

12.

Design, Synthesis, and Biological Evaluation of Hexacyclic Tetracyclines as Potent, Broad Spectrum Antibacterial Agents.

Sun C, Hunt DK, Chen CL, Deng Y, He M, Clark RB, Fyfe C, Grossman TH, Sutcliffe JA, Xiao XY.

J Med Chem. 2015 Jun 11;58(11):4703-12. doi: 10.1021/acs.jmedchem.5b00262. Epub 2015 May 20.

PMID:
25927406
13.

Eravacycline (TP-434) is efficacious in animal models of infection.

Grossman TH, Murphy TM, Slee AM, Lofland D, Sutcliffe JA.

Antimicrob Agents Chemother. 2015 May;59(5):2567-71. doi: 10.1128/AAC.04354-14. Epub 2015 Feb 17.

14.

Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli.

Grossman TH, O'Brien W, Kerstein KO, Sutcliffe JA.

Antimicrob Agents Chemother. 2015 Apr;59(4):2446-9. doi: 10.1128/AAC.04967-14. Epub 2015 Jan 26.

15.

In vitro susceptibility testing of eravacycline is unaffected by medium age and nonstandard assay parameters.

Grossman TH, Pillar CM, Sahm DF, Sutcliffe JA.

Antimicrob Agents Chemother. 2015 Apr;59(4):2426-7. doi: 10.1128/AAC.04727-14. Epub 2015 Jan 20.

16.

Antibiotics in interventional radiology.

Sutcliffe JA, Briggs JH, Little MW, McCarthy E, Wigham A, Bratby M, Tapping CR, Anthony S, Patel R, Phillips-Hughes J, Boardman P, Uberoi R.

Clin Radiol. 2015 Mar;70(3):223-34. doi: 10.1016/j.crad.2014.09.021. Epub 2014 Nov 24. Review.

PMID:
25459674
17.

Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections.

Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, Walpole SM, Horn PT.

Antimicrob Agents Chemother. 2014;58(4):1847-54. doi: 10.1128/AAC.01614-13. Epub 2013 Dec 16.

18.

Synthesis and biological evaluation of 8-aminomethyltetracycline derivatives as novel antibacterial agents.

Clark RB, He M, Deng Y, Sun C, Chen CL, Hunt DK, O'Brien WJ, Fyfe C, Grossman TH, Sutcliffe JA, Achorn C, Hogan PC, Katz CE, Niu J, Zhang WY, Zhu Z, Ronn M, Xiao XY.

J Med Chem. 2013 Oct 24;56(20):8112-38. doi: 10.1021/jm401211t. Epub 2013 Oct 3.

PMID:
24047201
19.

Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH.

Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26.

20.

Susceptibility of tetracyclines to Tet(a) resistance is independent of interdomain loop sequence.

Fyfe C, Sutcliffe JA, Grossman TH.

Antimicrob Agents Chemother. 2013 May;57(5):2430-1. doi: 10.1128/AAC.00393-13. Epub 2013 Mar 11. No abstract available.

21.

Development and characterization of a Pseudomonas aeruginosa in vitro coupled transcription-translation assay system for evaluation of translation inhibitors.

Fyfe C, Sutcliffe JA, Grossman TH.

J Microbiol Methods. 2012 Sep;90(3):256-61. doi: 10.1016/j.mimet.2012.05.018. Epub 2012 Jun 5.

22.

Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.

Grossman TH, Starosta AL, Fyfe C, O'Brien W, Rothstein DM, Mikolajka A, Wilson DN, Sutcliffe JA.

Antimicrob Agents Chemother. 2012 May;56(5):2559-64. doi: 10.1128/AAC.06187-11. Epub 2012 Feb 21. Erratum in: Antimicrob Agents Chemother. 2015 Sep;59(9):5870.

23.

Antibiotics in development targeting protein synthesis.

Sutcliffe JA.

Ann N Y Acad Sci. 2011 Dec;1241:122-52. doi: 10.1111/j.1749-6632.2011.06323.x. Review.

PMID:
22191530
24.

Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.

Clark RB, Hunt DK, He M, Achorn C, Chen CL, Deng Y, Fyfe C, Grossman TH, Hogan PC, O'Brien WJ, Plamondon L, Rönn M, Sutcliffe JA, Zhu Z, Xiao XY.

J Med Chem. 2012 Jan 26;55(2):606-22. doi: 10.1021/jm201467r. Epub 2012 Jan 6.

PMID:
22148555
25.

Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.

Xiao XY, Hunt DK, Zhou J, Clark RB, Dunwoody N, Fyfe C, Grossman TH, O'Brien WJ, Plamondon L, Rönn M, Sun C, Zhang WY, Sutcliffe JA.

J Med Chem. 2012 Jan 26;55(2):597-605. doi: 10.1021/jm201465w. Epub 2012 Jan 4.

PMID:
22148514
26.

Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant.

Hamouda T, Sutcliffe JA, Ciotti S, Baker JR Jr.

Clin Vaccine Immunol. 2011 Jul;18(7):1167-75. doi: 10.1128/CVI.00035-11. Epub 2011 May 4.

27.

8-Azatetracyclines: synthesis and evaluation of a novel class of tetracycline antibacterial agents.

Clark RB, He M, Fyfe C, Lofland D, O'Brien WJ, Plamondon L, Sutcliffe JA, Xiao XY.

J Med Chem. 2011 Mar 10;54(5):1511-28. doi: 10.1021/jm1015389. Epub 2011 Feb 8.

28.

Evolution and global dissemination of macrolide-resistant group A streptococci.

Robinson DA, Sutcliffe JA, Tewodros W, Manoharan A, Bessen DE.

Antimicrob Agents Chemother. 2006 Sep;50(9):2903-11.

29.

Improving on nature: antibiotics that target the ribosome.

Sutcliffe JA.

Curr Opin Microbiol. 2005 Oct;8(5):534-42. Review.

PMID:
16111914
30.

Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany.

Reinert RR, Lütticken R, Sutcliffe JA, Tait-Kamradt A, Cil MY, Schorn HM, Bryskier A, Al-Lahham A.

Antimicrob Agents Chemother. 2004 Apr;48(4):1369-73.

31.

Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy.

Butler JC, Lennox JL, McDougal LK, Sutcliffe JA, Tait-Kamradt A, Tenover FC.

Clin Infect Dis. 2003 Jan 15;36(2):e19-25. Epub 2003 Jan 7.

PMID:
12522763
32.

CJ-15,696 and its analogs, new furopyridine antibiotics from the fungus Cladobotryum varium: fermentation, isolation, structural elucidation, biotransformation and antibacterial activities.

Sakemi S, Bordner J, DeCosta DL, Dekker KA, Hirai H, Inagaki T, Kim YJ, Kojima N, Sims JC, Sugie Y, Sugiura A, Sutcliffe JA, Tachikawa K, Truesdell SJ, Wong JW, Yoshikawa N, Kojima Y.

J Antibiot (Tokyo). 2002 Jan;55(1):6-18.

33.

A novel antibiotic CJ-17,572 from a fungus, Pezicula sp.

Sugie Y, Dekker KA, Inagaki T, Kim YJ, Sakakibara T, Sakemi S, Sugiura A, Brennan L, Duignan J, Sutcliffe JA, Kojima Y.

J Antibiot (Tokyo). 2002 Jan;55(1):19-24.

34.

CJ-12,373, a novel topoisomerase II inhibitor: fermentation, isolation, structure elucidation and biological activities.

Inagaki T, Kaneda K, Suzuki Y, Hirai H, Nomura E, Sakakibara T, Yamauchi Y, Huang LH, Norcia M, Wondrack LM, Sutcliffe JA, Kojima N.

J Antibiot (Tokyo). 1998 Feb;51(2):112-6.

35.

CJ-12,371 and CJ-12,372, two novel DNA gyrase inhibitors. Fermentation,isolation, structural elucidation and biological activities.

Sakemi S, Inagaki T, Kaneda K, Hirai H, Iwata E, Sakakibara T, Yamauchi Y, Norcia M, Wondrack LM, Sutcliffe JA, et al.

J Antibiot (Tokyo). 1995 Feb;48(2):134-42.

36.

In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.

Gootz TD, Brighty KE, Anderson MR, Schmieder BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR.

Diagn Microbiol Infect Dis. 1994 Aug;19(4):235-43.

PMID:
7851087
37.

Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.

Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N.

J Biol Chem. 1991 Aug 5;266(22):14585-92.

38.

Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems.

Gootz TD, Barrett JF, Sutcliffe JA.

Antimicrob Agents Chemother. 1990 Jan;34(1):8-12. Review. No abstract available.

39.

In vitro assays used to measure the activity of topoisomerases.

Barrett JF, Sutcliffe JA, Gootz TD.

Antimicrob Agents Chemother. 1990 Jan;34(1):1-7. Review. No abstract available.

40.

Biochemical characteristics and physiological significance of major DNA topoisomerases.

Sutcliffe JA, Gootz TD, Barrett JF.

Antimicrob Agents Chemother. 1989 Dec;33(12):2027-33. Review. No abstract available.

41.

Supplemental Content

Loading ...
Support Center